-+ 0.00%
-+ 0.00%
-+ 0.00%

Immunic names Michael Bonney board chair, replacing interim chair Simona Skerjanec

PUBT·05/19/2026 10:30:23
Listen to the news
Immunic names Michael Bonney board chair, replacing interim chair Simona Skerjanec
  • Immunic appointed Michael W. Bonney as chair of the board, effective May 16, 2026.
  • Simona Skerjanec moved from interim chair to remain a board member.
  • Bonney previously held senior commercial leadership roles at Biogen, where he worked on the launch and growth of Avonex for multiple sclerosis.
  • He later served as CEO of Cubist Pharmaceuticals for more than 10 years, leading commercialization of Cubicin and the company’s sale to Merck for about USD 9.5 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2329356_en), on May 19, 2026, and is solely responsible for the information contained therein.